Cutler Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-300
| Closed | -$10K | – | 5825 |
|
|
2020
Q3 | $10K | Hold |
300
| – | – | ﹤0.01% | 3035 |
|
|
2020
Q2 | $5K | Buy |
300
+100
| +50% | +$1.7K | ﹤0.01% | 3395 |
|
|
2020
Q1 | $2K | Buy |
+200
| New | +$5.11K | ﹤0.01% | 3621 |
|
|
2019
Q4 | – | Sell |
-7,400
| Closed | -$207K | – | 4917 |
|
|
2019
Q3 | $154K | Buy |
7,400
+6,100
| +469% | +$125K | 0.01% | 829 |
|
|
2019
Q2 | $27K | Sell |
1,300
-2,000
| -61% | -$41.2K | ﹤0.01% | 2003 |
|
|
2019
Q1 | $73K | Buy |
3,300
+1,300
| +65% | +$30.6K | 0.01% | 1195 |
|
|
2018
Q4 | $47K | Sell |
2,000
-5,100
| -72% | -$132K | ﹤0.01% | 1517 |
|
|
2018
Q3 | $193K | Buy |
+7,100
| New | +$201K | 0.01% | 858 |
|
|
2018
Q2 | – | Sell |
-3,000
| Closed | -$91.8K | – | 5199 |
|
|
2018
Q1 | $95K | Buy |
+3,000
| New | +$106K | 0.01% | 1219 |
|
|
2017
Q4 | – | Sell |
-7,800
| Closed | -$252K | – | 6362 |
|
|
2017
Q3 | $193K | Buy |
7,800
+6,900
| +767% | +$149K | 0.01% | 1205 |
|
|
2017
Q2 | $18K | Buy |
900
+700
| +350% | +$13.4K | ﹤0.01% | 3552 |
|
|
2017
Q1 | $4K | Sell |
200
-400
| -67% | -$8.21K | ﹤0.01% | 4997 |
|
|
2016
Q4 | $12K | Sell |
600
-1,500
| -71% | -$30.7K | ﹤0.01% | 4042 |
|
|
2016
Q3 | $31K | Buy |
+2,100
| New | +$28.3K | ﹤0.01% | 2983 |
|
Cutler Group's AIMT Position: Q4 2020 in Review
Cutler Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 300 shares — an estimated $10K sold.
Cutler Group first reported a position in AIMT in Q3 2016 and held it in 14 quarters. The position peaked at $193K in Q3 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Cutler Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Cutler Group sold 300 Aimmune Therapeutics shares in Q4 2020, an estimated $10K.
- Cutler Group first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 14 quarters.
- Cutler Group's Aimmune Therapeutics position peaked at $193K in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Cutler Group's 13F filing for Q4 2020, filed 21 Jan 2021.